SI — SHOULDER INNOVATIONS, INC.

NYSE · Health Care · Health Care Equipment & Supplies · CIK 1699350 ·
Last close
$20.16
Market Cap
$418.08M
52W High
$22.92
52W Low
$12.06
ADV30
132,527
Next earnings
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 16,708,000 12,986,000 -8,976,000 -8,379,000 160,361,000 11,492,000 27,344,000
Dec 2025 14,416,000 11,057,000 -8,500,000 -7,772,000 169,907,000 26,871,000 29,157,000
Sep 2025 11,756,000 8,961,000 -7,641,000 -8,729,000 177,762,000 54,934,000 29,930,000
Jun 2025 11,013,000 8,393,000 -5,862,000 -19,196,000 77,829,000 27,054,000 156,029,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-34,493,000
Investing CF
$-85,649,000
Financing CF
$125,264,000
CapEx
$-9,300,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.38
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-105,779,000
Inventory
$21,829,000
Receivables
$10,546,000
ST Investments
$97,046,000
EBIT TTM
$-44,970,000
Pretax Income TTM
$-44,076,000
Interest Exp TTM
$70,000
Analysts
4

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 47,317,000 -26,297,000 -40,359,000 169,907,000 29,157,000 -28,612,000
Dec 2024 31,623,000 -14,653,000 -15,619,000 43,080,000 97,775,000 -14,143,000
Dec 2023 19,274,000 -10,864,000 -12,655,000 54,294,000 94,031,000 -13,144,000

TTM Snapshot

Revenues TTM
$7,454,000
NetIncome TTM
$-4,055,000
OpCashFlow TTM
$0
Assets (Latest)
$43,080,000
Forward EPS

Peers — same industry

TickerNameMarket CapLastDaily %
MOBI Mobia Medical, Inc. $405.31M $12.19
DCTH DELCATH SYSTEMS, INC. $449.13M $13.01
ELMD Electromed, Inc. $377.98M $45.65
OFIX Orthofix Medical Inc. $470.10M $11.63
KIDS ORTHOPEDIATRICS CORP $522.18M $20.33

News headlines (Yahoo Finance, 1h cache)

Shoulder Innovations Announces Closing of up to $50 Million Credit Facility
2026-06-29 11:00 · Yahoo
Wall Street Analysts See a 51.79% Upside in Shoulder Innovations, Inc. (SI): Can the Stock Really Move This High?
2026-06-03 13:55 · Yahoo
Shoulder Innovations to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
2026-05-26 20:05 · Yahoo
Wall Street Analysts Think Shoulder Innovations, Inc. (SI) Could Surge 35.96%: Read This Before Placing a Bet
2026-05-18 13:55 · Yahoo
Shoulder Innovations, Inc. (NYSE:SI) Just Released Its First-Quarter Earnings: Here's What Analysts Think
2026-05-16 13:59 · Yahoo
Shoulder Innovations Q1 Earnings Call Highlights
2026-05-15 08:09 · Yahoo
Shoulder Innovations, Inc. (SI) Reports Q1 Loss, Tops Revenue Estimates
2026-05-13 21:35 · Yahoo
Shoulder Innovations Q1 2026 Earnings Call Transcript
2026-05-13 21:32 · Yahoo
Shoulder Innovations Reports First Quarter 2026 Financial Results and Raises Full Year Outlook
2026-05-13 20:05 · Yahoo
Viatris (VTRS) Q1 Earnings and Revenues Surpass Estimates
2026-05-07 12:50 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.